4.7 Article

Clinical Applications of DNA Vaccines: Current Progress

Journal

CLINICAL INFECTIOUS DISEASES
Volume 53, Issue 3, Pages 296-302

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir334

Keywords

-

Funding

  1. National Institutes of Health [R01AI092843]
  2. National Institute of Allergy and Infectious Diseases [PO1-AI071739]

Ask authors/readers for more resources

It was discovered almost 20 years ago that plasmid DNA, when injected into the skin or muscle of mice, could induce immune responses to encoded antigens. Since that time, there has since been much progress in understanding the basic biology behind this deceptively simple vaccine platform and much technological advancement to enhance immune potency. Among these advancements are improved formulations and improved physical methods of delivery, which increase the uptake of vaccine plasmids by cells; optimization of vaccine vectors and encoded antigens; and the development of novel formulations and adjuvants to augment and direct the host immune response. The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas. This review focuses on these advances and discusses both preventive and immunotherapeutic clinical applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available